These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21461842)

  • 1. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
    Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
    Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
    Chauhan SC; Singh AP; Ruiz F; Johansson SL; Jain M; Smith LM; Moniaux N; Batra SK
    Mod Pathol; 2006 Oct; 19(10):1386-94. PubMed ID: 16880776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.
    Cramer DW; Williams K; Vitonis AF; Yamamoto HS; Stuebe A; Welch WR; Titus L; Fichorova RN
    Cancer Causes Control; 2013 Nov; 24(11):1911-23. PubMed ID: 23925696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.
    Williams KA; Terry KL; Tworoger SS; Vitonis AF; Titus LJ; Cramer DW
    PLoS One; 2014; 9(2):e88334. PubMed ID: 24551091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
    Hamanaka Y; Suehiro Y; Fukui M; Shikichi K; Imai K; Hinoda Y
    Int J Cancer; 2003 Jan; 103(1):97-100. PubMed ID: 12455059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.
    Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA
    Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
    Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
    Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
    Zamarin D; Walderich S; Holland A; Zhou Q; Iasonos AE; Torrisi JM; Merghoub T; Chesebrough LF; Mcdonnell AS; Gallagher JM; Li Y; Hollmann TJ; Grisham RN; Erskine CL; Block MS; Knutson KL; O'Cearbhaill RE; Aghajanian C; Konner JA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
    Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L
    Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
    Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
    Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
    Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.
    Blixt O; Bueti D; Burford B; Allen D; Julien S; Hollingsworth M; Gammerman A; Fentiman I; Taylor-Papadimitriou J; Burchell JM
    Breast Cancer Res; 2011 Mar; 13(2):R25. PubMed ID: 21385452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody biomarkers for the detection of serous ovarian cancer.
    Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
    Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
    Jain S; Nadeem N; Ulfenborg B; Mäkelä M; Ruma SA; Terävä J; Huhtinen K; Leivo J; Kristjansdottir B; Pettersson K; Sundfeldt K; Gidwani K
    Int J Cancer; 2022 Oct; 151(7):1175-1184. PubMed ID: 35531590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
    Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
    J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies.
    Da Gama Duarte J; Quigley LT; Young AR; Hayashi M; Miyazawa M; Lopata A; Mancuso N; Mikami M; Behren A; Meeusen E
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
    von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; van Kamp GJ; Kok A; van Uffelen K; Snijdewint FG; Paul MA; Meijer S; Hilgers J
    Tumour Biol; 1998; 19(3):186-95. PubMed ID: 9591045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.
    Ricardo S; Marcos-Silva L; Valente C; Coelho R; Gomes R; David L
    Virchows Arch; 2016 Jun; 468(6):715-22. PubMed ID: 27003157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.